Durable disease control of adult-onset xanthogranuloma with time-limited mitogen-activated extracellular kinase inhibition: a case report

British Journal of Dermatology 2026

View at publisher
Authors: Hyun Lee, Ellie A. McCabe, Thuy N. Ho, Mark Cameron Mochel, Ariel D. Sindel, Andrew Stewart Poklepovic
DOI: 10.1093/bjd/ljag047
Cited by: 0
References: 5

Abstract

Xanthogranuloma with mitogen-activated protein kinase pathway-activating mutations, such as the GAB2::BRAF fusion, may respond to mitogen-activated extracellular kinase (MEK) inhibitors, even in adult-onset cases. However, MEK inhibitors can cause delayed cardiotoxicity, even in patients with good initial tolerance, highlighting the need for close toxicity monitoring. This underscores the importance of treatment cessation trials, which may be reasonable to consider after 1–5 years of therapy, even if the disease was initially extremely aggressive.

Fields of Study & Subjects

Histiocytic Disorders and Treatments Melanoma and MAPK Pathways Genetic and rare skin diseases.

Publication details

Journal / source
British Journal of Dermatology
Volume
194
Issue
5
Pages
979–981
Publication date
10 February 2026
Language
EN